The ability of biomarker changes at 2 months to act as a surrogate endpoint. Soluble BAFF was measured as a ratio of the 2-month value compared with the initial value for each patient. Nonresponders (■) were compared with responders (▴) as determined by a clinical response at 9 months. The difference is significant (P = .05).